Tag: meningococcal vaccines market demand

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Meningococcal Vaccines Market From 2025 To 2034?

The meningococcal vaccines market has experienced significant growth in recent years. Projections indicate it will expand from $3.89 billion in 2024 to $4.26 billion in 2025, driven by a compound annual growth rate (CAGR) of 9.3%. This historical expansion can be attributed to factors such as disease incidence, global travel trends, enhancements in healthcare infrastructure, epidemic preparedness, and the scope of health insurance coverage.

The market for meningococcal vaccines is projected to experience robust expansion in the coming years. This market is anticipated to reach $6.05 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.2%. Several factors contribute to this projected growth, including the appearance of novel strains, rising globalization, increased healthcare spending, various health programs, and an evolving regulatory environment. Key developments expected during this period encompass personalized vaccines, electronic vaccination records, gene editing advancements, multi-valent vaccine formulations, and subscription-based vaccine access models.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Are The Key Drivers Of Growth In The Meningococcal Vaccines Market?

An expected rise in healthcare spending is poised to accelerate the expansion of the meningococcal vaccine market. Healthcare, in this context, refers to residential care institutions, nursing facilities, and intermediate care facilities for individuals with mental illnesses or retardation. The high cost associated with new vaccine generations, when contrasted with their predecessors, has become central to debates regarding whether their benefits warrant the price. Consequently, assessing the comprehensive social and economic benefits of vaccination is an increasingly vital area of study. Illustratively, healthcare spending in the United States surged by 9.7% to $4.1 trillion, or $12,530 per person, in May 2022, according to an article published by the American Medical Association. This growth pace was notably higher than the 4.3% recorded in 2019. Therefore, this upward trend in healthcare spending is a primary impetus for the growth of the meningococcal vaccine market.

What Are The Leading Segments Analyzed In The Meningococcal Vaccines Market?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Which Trends Are Impacting The Meningococcal Vaccines Market?

Leading companies within the meningococcal vaccines market are focusing on the development of novel vaccines to prevent various serogroups, aiming to enhance their market profitability. These vaccines serve as a prophylactic measure, safeguarding individuals from infections attributed to particular serogroups of the Neisseria meningitidis bacteria. An example of this is Pfizer Inc., a pharmaceutical company based in the US, which secured FDA approval for its PENBRAYA vaccine in October 2023. PENBRAYA stands out as the most extensive U.S.-approved meningococcal vaccine, offering protection across a broad spectrum of serogroups, specifically A, B, C, W, and Y. The FDA’s endorsement was based on strong Phase 2 and 3 trial results, which demonstrated immunogenicity comparable to Trumenba + Menveo for all serogroups, alongside a positive safety profile. Furthermore, Pfizer had announced in September 2022 the encouraging findings from a Phase 3 trial, which assessed PENBRAYA’s safety, tolerability, and immunogenicity against other currently licensed meningococcal vaccines.

Who Are The Key Multinational Companies Dominating The Meningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Bio-Manguinhos, Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Hualan Biological Engineering Inc., China National Pharmaceutical Group (Sinopharm), Bharat Biotech, Incepta Pharmaceuticals Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co. Ltd., Biokangtai, Biomed Pvt Ltd., Biocine SCL, Panacea Biotec Ltd., Grifols S.A., CSL Limited, Minhai Biotechnology Co. Ltd., Chiron Behring Vaccines Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

What Are The Regional Market Dynamics Impacting The Meningococcal Vaccines Industry?

North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Meningococcal Vaccines Market Report:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

Browse Through More Reports Similar to the Global Meningococcal Vaccines Market 2025, By The Business Research Company

Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Pediatric Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report

Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Meningococcal Vaccines Market From 2025 To 2034?

The meningococcal vaccines market has experienced significant growth in recent years. Projections indicate it will expand from $3.89 billion in 2024 to $4.26 billion in 2025, driven by a compound annual growth rate (CAGR) of 9.3%. This historical expansion can be attributed to factors such as disease incidence, global travel trends, enhancements in healthcare infrastructure, epidemic preparedness, and the scope of health insurance coverage.

The market for meningococcal vaccines is projected to experience robust expansion in the coming years. This market is anticipated to reach $6.05 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.2%. Several factors contribute to this projected growth, including the appearance of novel strains, rising globalization, increased healthcare spending, various health programs, and an evolving regulatory environment. Key developments expected during this period encompass personalized vaccines, electronic vaccination records, gene editing advancements, multi-valent vaccine formulations, and subscription-based vaccine access models.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Are The Key Drivers Of Growth In The Meningococcal Vaccines Market?

An expected rise in healthcare spending is poised to accelerate the expansion of the meningococcal vaccine market. Healthcare, in this context, refers to residential care institutions, nursing facilities, and intermediate care facilities for individuals with mental illnesses or retardation. The high cost associated with new vaccine generations, when contrasted with their predecessors, has become central to debates regarding whether their benefits warrant the price. Consequently, assessing the comprehensive social and economic benefits of vaccination is an increasingly vital area of study. Illustratively, healthcare spending in the United States surged by 9.7% to $4.1 trillion, or $12,530 per person, in May 2022, according to an article published by the American Medical Association. This growth pace was notably higher than the 4.3% recorded in 2019. Therefore, this upward trend in healthcare spending is a primary impetus for the growth of the meningococcal vaccine market.

What Are The Leading Segments Analyzed In The Meningococcal Vaccines Market?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Which Trends Are Impacting The Meningococcal Vaccines Market?

Leading companies within the meningococcal vaccines market are focusing on the development of novel vaccines to prevent various serogroups, aiming to enhance their market profitability. These vaccines serve as a prophylactic measure, safeguarding individuals from infections attributed to particular serogroups of the Neisseria meningitidis bacteria. An example of this is Pfizer Inc., a pharmaceutical company based in the US, which secured FDA approval for its PENBRAYA vaccine in October 2023. PENBRAYA stands out as the most extensive U.S.-approved meningococcal vaccine, offering protection across a broad spectrum of serogroups, specifically A, B, C, W, and Y. The FDA’s endorsement was based on strong Phase 2 and 3 trial results, which demonstrated immunogenicity comparable to Trumenba + Menveo for all serogroups, alongside a positive safety profile. Furthermore, Pfizer had announced in September 2022 the encouraging findings from a Phase 3 trial, which assessed PENBRAYA’s safety, tolerability, and immunogenicity against other currently licensed meningococcal vaccines.

Who Are The Key Multinational Companies Dominating The Meningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Bio-Manguinhos, Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Hualan Biological Engineering Inc., China National Pharmaceutical Group (Sinopharm), Bharat Biotech, Incepta Pharmaceuticals Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co. Ltd., Biokangtai, Biomed Pvt Ltd., Biocine SCL, Panacea Biotec Ltd., Grifols S.A., CSL Limited, Minhai Biotechnology Co. Ltd., Chiron Behring Vaccines Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

What Are The Regional Market Dynamics Impacting The Meningococcal Vaccines Industry?

North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Meningococcal Vaccines Market Report:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

Browse Through More Reports Similar to the Global Meningococcal Vaccines Market 2025, By The Business Research Company

Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Pediatric Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report

Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Meningococcal Vaccines Industry By 2029?

The market size for meningococcal vaccines has exhibited substantial growth recently. The market value is anticipated to increase from $3.89 billion in 2024 to $4.26 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 9.3%. Factors such as disease occurrence rates, trends in global travel, the state of health care infrastructure, the level of preparedness for epidemics, and the extent of health insurance coverage have all contributed to this historical growth.

In the coming years, the meningococcal vaccines market is projected to witness robust expansion. The market is set to escalate to “$6.05 billion by 2029, with a compound annual growth rate (CAGR) of 9.2%. The projected growth in this duration can be ascribed to the appearance of new strains, escalating globalization, burgeoning healthcare investments, health initiatives, and alteration in regulatory frameworks. Key trends expected throughout the forecast period encompass customized vaccines, electronic vaccination records, gene alteration technologies, multi-valent vaccines, and recurring-subscription vaccine models.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

Which Demand Drivers Are Strengthening The Meningococcal Vaccines Market?

The anticipated surge in healthcare expenditure is predicted to fuel the expansion of the meningococcal vaccine market. The term healthcare encompasses facilities such as residences for care, nursing homes, intermediate care institutions for those suffering from mental illnesses or retardation. The high cost associated with newer iterations of vaccines, in comparison to earlier versions, has sparked debates about the economic viability of these advancements. The comprehensive assessment of the social and economic boons brought about by vaccination is increasingly being explored in academic discourse around vaccine valuation. As an example, a May 2022 report from the American Medical Association, a prominent association and advocacy group for physicians and medical students in the United States, revealed that healthcare expenditure in the country had grown by 9.7%, amounting to $4.1 trillion or $12,530 per capita. This rate of growth substantially overpowers that of 2019, which was at 4.3%. Consequently, a rise in healthcare spending is propelling the progress of the meningococcal vaccine market.

What Are The Key Segment Trends Observed In The Meningococcal Vaccines Market?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Which Disruptive Trends Are Driving Change Across The Meningococcal Vaccines Market?

Leading businesses in the meningococcal vaccines market are focusing on the creation of novel vaccines to prevent various serogroups, aiming to enhance their market profitability. Meningococcal vaccines serve as a preventative method to shield people from infections prompted by certain serogroups of the bacteria Neisseria meningitidis. For instance, in October 2023, Pfizer Inc., an American pharmaceutical firm, obtained FDA approval for the vaccine PENBRAYA. PENBRAYA offers substantial serogroup coverage and is the most exhaustive meningococcal vaccine authorized in the U.S, providing protection against groups A, B, C, W, and Y. The FDA approval is based on substantial Phase 2 and 3 trial data that proves it’s not inferior in immunogenicity to Trumenba + Menveo across all serogroups, in addition to a favourable safety profile. In September 2022, Pfizer announced encouraging results from a Phase 3 trial comparing the safety, tolerability, and immunogenicity of PENBRAYA with other licensed meningococcal vaccines.

Which Companies Are Contributing Significantly To The Meningococcal Vaccines Market Growth?

Major companies operating in the meningococcal vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Bio-Manguinhos, Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Hualan Biological Engineering Inc., China National Pharmaceutical Group (Sinopharm), Bharat Biotech, Incepta Pharmaceuticals Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co. Ltd., Biokangtai, Biomed Pvt Ltd., Biocine SCL, Panacea Biotec Ltd., Grifols S.A., CSL Limited, Minhai Biotechnology Co. Ltd., Chiron Behring Vaccines Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Which Region Is Forecasted To Lead The Meningococcal Vaccines Market In The Coming Years?

North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Meningococcal Vaccines Market From 2025 to 2029?

Over the past few years, the meningococcal vaccines industry has seen robust growth. The market value is predicted to rise from $3.89 billion in 2024 to $4.26 billion in 2025, thanks to a compound annual growth rate (CAGR) of 9.3%. The expansion in the historical period was driven by factors such as the prevalence of disease, global travel patterns, the state of healthcare infrastructure, preparedness for epidemics, and the coverage of health insurance.

The market size of meningococcal vaccines is poised for substantial growth in the coming years, with projections noting a growth to “$6.05 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. Reasons driving the growth during this forecasted period include the emergence of new strains, an increase in globalization, rising healthcare investments, health initiatives, and a transforming regulatory environment. Notable trends expected during this forecasted timeframe encompass personalized vaccines, the implementation of digital vaccination records, the advent of gene editing technologies, the development of multi-valent vaccines, and the introduction of subscription-based vaccine models.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Elements Are Contributing To Growth In The Meningococcal Vaccines Market?

The anticipated surge in healthcare spending is predicted to accelerate the growth of the meningococcal vaccine market. Healthcare, in this context, encompasses facilities like residential care establishments, nursing homes, or intermediate care centers for individuals with mental illnesses or mental retardation. The fact that newer vaccine generations tend to be more expensive than their older counterparts is widely debated, particularly in terms of whether the vaccines’ advantages outweigh their costs. Thorough appraisal of both the societal and fiscal benefits of vaccinations has become an essential research aspect in literature that evaluates vaccination. For example, an article by the American Medical Association in May 2022 highlighted that US healthcare expenditures have risen by 9.7%, equating to $4.1 trillion or $12,530 per individual. This growth rate vastly surpasses that of 2019, which was 4.3%. Consequently, the augmentation in healthcare expenses is influencing the upswing in the meningococcal vaccine market.

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

How Are Key Trends Driving Expansion In The Meningococcal Vaccines Industry?

Leading businesses in the meningococcal vaccines market are focusing on creating new vaccines to combat specific serogroups, which, in turn, will amplify their market earnings. Meningococcal vaccines serve as protective measures against infections triggered by certain serogroups of the bacterium Neisseria meningitidis. For instance, Pfizer Inc., a pharmaceutical firm based in the US, obtained FDA approval in October 2023 for their vaccine PENBRAYA. PENBRAYA, being capable of extensive coverage against serogroups, became the most all-inclusive meningococcal vaccine approved in the U.S., providing protection against groups A, B, C, W, and Y. The FDA’s approval was based on compelling Phase 2 and 3 trial results, which demonstrated the vaccine’s comparable immunogenicity to Trumenba + Menveo across all serogroups, along with a favorable safety profile. In September 2022, Pfizer released promising results from a Phase 3 trial, where PENBRAYA outperformed already licensed meningococcal vaccines in terms of safety, tolerability, and immunogenicity.

Who Are The Key Contributors To Growth In The Meningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Bio-Manguinhos, Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Hualan Biological Engineering Inc., China National Pharmaceutical Group (Sinopharm), Bharat Biotech, Incepta Pharmaceuticals Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co. Ltd., Biokangtai, Biomed Pvt Ltd., Biocine SCL, Panacea Biotec Ltd., Grifols S.A., CSL Limited, Minhai Biotechnology Co. Ltd., Chiron Behring Vaccines Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd.

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Which Region Is Projected To Lead The Meningococcal Vaccines Market By 2025?

North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Meningococcal Vaccines Market Growth in 2025?

The market for meningococcal vaccines has experienced rapid expansion in the past few years. It’s projected to rise from $3.89 billion in 2024 to $4.29 billion in 2025, with a compound annual growth rate (CAGR) of 10.3%. Factors contributing to growth during this historical period include the frequency of the disease, global travel patterns, the quality of healthcare infrastructure, epidemic readiness, and the scope of health insurance coverage.

What Is the Forecast for the Meningococcal Vaccines Market Size Through 2029?

The market size for meningococcal vaccines is anticipated to exhibit robust growth in the upcoming years, with projections suggesting a rise to $6.18 billion by 2029. This surges at a compound annual growth rate (CAGR) of 9.5%. Factors contributing to growth in the projected period include the emergence of new strains, increased globalization, escalating healthcare investments, health initiatives, and an evolving regulatory environment. Notable market trends during the forecast period include the development of personalized vaccines, the emergence of digital vaccination records, gene editing technologies, multi-valent vaccines, and subscription-based vaccine models.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What are the Key Market Players in Meningococcal Vaccines Market and How They’re Evolving?

Major companies operating in the meningococcal vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Bio-Manguinhos, Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Hualan Biological Engineering Inc., China National Pharmaceutical Group (Sinopharm), Bharat Biotech, Incepta Pharmaceuticals Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co. Ltd., Biokangtai, Biomed Pvt Ltd., Biocine SCL, Panacea Biotec Ltd., Grifols S.A., CSL Limited, Minhai Biotechnology Co. Ltd., Chiron Behring Vaccines Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd.

What Are the Primary Growth Drivers in the Meningococcal Vaccines Market?

The meningococcal vaccine market is expected to expand due to projected rise in healthcare expenditures. Healthcare implies an array of medical care facilities, including residential care institutions, nursing homes, and intermediate care facilities for individuals with mental disorders or impairments. The substantial cost of newer vaccine generations in comparison to older ones has ignited debates concerning the justification of these high prices against their benefits. Evaluating the comprehensive societal and economical benefits of vaccines is gaining increased scholarly interest in vaccination value studies. For example, a May 2022 report by the American Medical Association, a renowned organization composed of physicians and medical students in the U.S, revealed that the country’s healthcare spending had surged by 9.7% to $4.1 trillion or $12,530 per capita. This growth rate is distinctly more significant than that recorded in 2019 (4.3%). Thus, higher healthcare spending is contributing to the progression of the meningococcal vaccine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

What Are the Leading Segments in the Global Meningococcal Vaccines Industry?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

What Are the Key Market Trends in the Meningococcal Vaccines Industry?

Prominent corporations in the meningococcal vaccines industry are focusing on the creation of new vaccines for the prevention of specific serogroups to boost their market profitability. Meningococcal vaccines serve as preventative defense mechanisms against infections caused by distinct serogroups of the Neisseria meningitidis bacteria. For illustration, in October 2023, Pfizer Inc., a pharmaceutical firm based out of the United States, obtained FDA authorization for its vaccine, PENBRAYA. With a broad range of serogroup coverage, PENBRAYA positions as the most comprehensive meningococcal vaccine sanctioned in the U.S., providing safety against A, B, C, W, and Y groups. The FDA endorsement is based on substantial Phase 2 and 3 trial information, verifying the vaccine’s immunogenicity, equal to Trumenba + Menveo across all serogroups, along with a favorable safety record. A recent announcement in September 2022 from Pfizer shared encouraging results from a Phase 3 trial where PENBRAYA was compared with other licensed meningococcal vaccines, evaluating safety, tolerability, and immunogenicity.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

What Is the Regional Outlook for the Meningococcal Vaccines Market?

North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8013

This Report Delivers Insight On:

1. How big is the meningococcal vaccines market, and how is it changing globally?

2. Who are the major companies in the meningococcal vaccines market, and how are they performing?

3. What are the key opportunities and risks in the meningococcal vaccines market right now?

4. Which products or customer segments are growing the most in the meningococcal vaccines market?

5. What factors are helping or slowing down the growth of the meningococcal vaccines market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the meningococcal vaccines industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Are the Key Milestones in the Meningococcal Vaccines Market’s Growth Trajectory From 2025 To 2034?#_x000D_

In the past few years, there has been a swift growth in the size of the meningococcal vaccines market. This market is projected to expand from $3.89 billion in 2024 to $4.29 billion in 2025, showcasing a compound annual growth rate (CAGR) of 10.3%. Factors such as disease prevalence, international travel habits, healthcare framework, readiness for epidemics, and health insurance are responsible for the significant growth throughout the historic phase._x000D_

_x000D_

The market size of meningococcal vaccines is forecasted to experience robust growth in the coming years, reaching $6.18 billion in 2029 with a compound annual growth rate (CAGR) of 9.5%. The anticipated growth in the forecast period could be as a result of factors such as the development of new strains, rising globalization, expanded healthcare investments, health initiatives, and evolving regulatory framework. Key trends anticipated during the forecast period comprise personalized vaccines, digital documentation of vaccinations, gene modification technologies, multi-valent vaccines, and vaccines models based on a subscription system._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp_x000D_

_x000D_

#Which Major Market Drivers Are Expected to Boost the Growth Potential of the Meningococcal Vaccines Market?#_x000D_

The meningococcal vaccine market’s expansion is predicted to be fuelled by a surge in healthcare expenditure. In this context, healthcare encompasses residential care institutions, nursing facilities, intermediate care centers for individuals battling mental illnesses, and those catered to people with intellectual disabilities. The costliness of the latest vaccine iterations compared to the older versions has sparked debates regarding whether the benefits these new vaccines provide justify their high costs. An immersive study into the comprehensive social and economic benefits of vaccination is increasingly being emphasized in the research to evaluate vaccination. To illustrate, an article by the American Medical Association, reported in May 2022 that there was an increase of 9.7% in US healthcare expenditure, taking it to $4.1 trillion, or $12,530 per person. This growth rate substantially outpaced the rate in 2019 (4.3%). It is, thus, clear that the escalation in healthcare spending is primarily responsible for the growth witnessed in the meningococcal vaccine market._x000D_

_x000D_

#Which Key Market Segments Comprise the Meningococcal Vaccines Market and Drive Its Revenue Growth?#_x000D_

The meningococcal vaccines market covered in this report is segmented –_x000D_

_x000D_

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine_x000D_

2) By Serotype: Men Acwy, Men B/Bc, Men C_x000D_

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults_x000D_

4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels_x000D_

5) By End user: Hospitals, Research, Academic Institutes_x000D_

_x000D_

Subsegments:_x000D_

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine_x000D_

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine_x000D_

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp_x000D_

_x000D_

#Which Areas Are Leading Regions in the Meningococcal Vaccines Market Expansion Across the Globe?#_x000D_

North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Key Market Trends in theMeningococcal Vaccines Market Over the Coming Years?#_x000D_

Leading firms in the meningococcal vaccines market are innovating new vaccines to guard against specific serogroups, striving to enhance their market profitability. Meningococcal vaccines serve as a protective shield against infections triggered by certain serogroups of the Neisseria meningitidis bacteria. For example, Pfizer Inc., an American pharmaceutical enterprise, gained FDA approval for its vaccine, PENBRAYA, in October 2023. PENBRAYA, offering comprehensive serogroup protection, stands as the most complete US-approved meningococcal vaccine, defending against groups A, B, C, W, and Y. Its approval by the FDA is based on strong data from Phase 2 and 3 trials, validating its non-inferior immunogenicity to Trumenba + Menveo across all serogroups and attesting to its favorable safety profile. Pfizer announced favorable results from a Phase 3 trial that showcased PENBRAYA’s comparability to currently licensed meningococcal vaccines in safety, tolerability, and immunogenicity in September 2022._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report_x000D_

_x000D_

#How Is the Meningococcal Vaccines Market Conceptually Defined?#_x000D_

Meningococcal vaccinations are vaccines that protect against meningococcal meningitis, an infection with the bacterium Neisseria meningitides that leads to inflammation of the tissues that surround the brain and spinal cord._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8013_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Factors Are Propelling the Market Growth of theMeningococcal Vaccines Market from 2025 to 2034?

The meningococcal vaccine market’s expansion is projected to be spurred by an anticipated increase in healthcare expenditure. Healthcare can be defined as the services provided by residential care institutions, nursing facilities, intermediate care providers for those suffering from mental health issues, or intermediate care providers for mentally challenged individuals. The significant cost of newer vaccine generations as opposed to their forerunners has become a central consideration when arguing if the benefits of the newer vaccinations warrant their higher costs. The importance of evaluating the overall societal and economic benefits of immunization is an emerging topic of investigation within the scholarship on vaccination value. For example, a report by the American Medical Association, a professional and lobbying organization for physicians and medical students in the US, from May 2022 states that American healthcare spending had surged by 9.7% to $4.1 trillion, equating to $12,530 per individual. This growth rate far surpasses that of 2019 (4.3%), indicating that a rise in healthcare expenditure is propelling the meningococcal vaccine market forward.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What is the Predicted Annual Growth Rate of theMeningococcal Vaccines Market Impact Industry Trends by 2034?

The size of the market for meningococcal vaccines has seen a swift expansion in recent times. It is projected to rise from $3.89 billion in 2024 to a higher bracket of $4.29 billion in 2025, signifying a compound annual growth rate (CAGR) of 10.3%. Factors contributing to growth during the historic period include disease prevalence, international travel tendencies, the state of healthcare systems, readiness for epidemics, and the extent of health insurance coverage.

The market size of meningococcal vaccines is predicted to experience significant expansion in the upcoming years, reaching a value of $6.18 billion in 2029 with a compound annual growth rate (CAGR) of 9.5%. The anticipated development in the forecast timeframe can be linked to the emergence of new strains, increased globalization, expanding healthcare investments, health initiatives, and shifting regulations. Notable trends in the projection period encompass customized vaccines, electronic vaccination records, gene modification technologies, multi-valent vaccines, and subscription-based immunization models.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8013

How Are Market Trends and Innovations Revolutionizing theMeningococcal Vaccines Industry in Recent Times?

Leading corporations in the meningococcal vaccines market are innovating new vaccines to prevent serogroups, thereby improving their market profit margins. These vaccines serve as defensive strategies against infections from specified serogroups of the bacterial strain Neisseria meningitidis. For example, Pfizer Inc., an American pharmaceutical establishment, won the FDA’s approval for its vaccine, PENBRAYA, in October 2023. PENBRAYA is the most comprehensive meningococcal vaccine sanctioned in the United States, offering wide serogroup coverage, protecting against A, B, C, W, and Y groups. The FDA’s approval was based on compelling data from Phase 2 and 3 clinical trials, that corroborated its immunogenicity, on par with Trumenba + Menveo across all serogroups while also being safe. Positive results from a Phase 3 trial of PENBRAYA, launched in September 2022 by Pfizer, showcased its effectiveness against other licensed meningococcal vaccines in safety, tolerability, and immunogenicity.

Which Key Market Players Are Shaping the Future and Growth of theMeningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Bio-Manguinhos, Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Hualan Biological Engineering Inc., China National Pharmaceutical Group (Sinopharm), Bharat Biotech, Incepta Pharmaceuticals Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co. Ltd., Biokangtai, Biomed Pvt Ltd., Biocine SCL, Panacea Biotec Ltd., Grifols S.A., CSL Limited, Minhai Biotechnology Co. Ltd., Chiron Behring Vaccines Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

What Are the Core Segments of the Meningococcal Vaccines Market, and How Do They Contribute to Growth?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

What Regions Are Dominating the Meningococcal Vaccines Market Growth?

North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Meningococcal Vaccines Market 2025, By The Business Research Company:

Soap And Cleaning Compounds Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/soap-and-cleaning-compounds-global-market-report

Hand Cream and Hand Lotion Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hand-cream-and-hand-lotions-global-market-report

Next-Generation Personalized Beauty Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/next-generation-personalized-beauty-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: